Promis Neurosciences (PMN) Projected to Release Earnings on Wednesday

Promis Neurosciences (NASDAQ:PMN) is anticipated to issue its Q3 2026 resultson Wednesday, November 11th. Analysts expect Promis Neurosciences to post earnings of ($1.26) per share for the quarter. Investors can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

Promis Neurosciences (NASDAQ:PMN) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.38) by $0.10. On average, analysts expect Promis Neurosciences to post ($5.07) EPS for the current fiscal year and ($3.77) EPS for the next fiscal year.

Promis Neurosciences Price Performance

NASDAQ:PMN traded down $0.20 during trading hours on Wednesday, reaching $3.21. The company’s stock had a trading volume of 107,574 shares, compared to its average volume of 118,805. The company has a market cap of $28.83 million, a price-to-earnings ratio of -0.38 and a beta of -0.19. Promis Neurosciences has a one year low of $2.78 and a one year high of $27.40. The business’s 50-day moving average is $10.79 and its 200-day moving average is $12.81.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on PMN shares. Weiss Ratings raised Promis Neurosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday. Roth Capital lowered their price objective on Promis Neurosciences to $15.00 and set a “buy” rating on the stock in a report on Monday. Chardan Capital set a $20.00 price objective on Promis Neurosciences and gave the company a “buy” rating in a research note on Monday, July 27th. Wall Street Zen upgraded Promis Neurosciences from a “strong sell” rating to a “sell” rating in a report on Saturday, July 18th. Finally, Guggenheim restated a “buy” rating and issued a $69.00 target price (up from $35.00) on shares of Promis Neurosciences in a report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $30.50.

Insider Activity at Promis Neurosciences

In other Promis Neurosciences news, insider Neil Cashman acquired 10,000 shares of the company’s stock in a transaction dated Monday, November 2nd. The shares were acquired at an average cost of $3.86 per share, for a total transaction of $38,600.00. Following the completion of the purchase, the insider owned 14,532 shares of the company’s stock, valued at approximately $56,093.52. This trade represents a 220.65% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 1.50% of the company’s stock.

About Promis Neurosciences

ProMIS Neurosciences Inc (NASDAQ: PMN) is a clinical-stage biotechnology company developing precision medicines for neurodegenerative diseases. The company’s research focuses on misfolded proteins, which can form toxic structures associated with conditions such as Alzheimer’s disease, amyotrophic lateral sclerosis and other neurological disorders.

ProMIS uses its proprietary target-discovery platform to identify disease-specific toxic protein conformations and develop antibodies intended to selectively bind and neutralize them while avoiding healthy forms of the same proteins.